EGFR and cancer: Histological analyses of xenograft tumours derived from these cell lines confirmed SCLC histology and expression of neuroendocrine (NE) markers in contrast to xenograft tumours derived from a resistant EGFR mutant cancer that maintained NSCLC histology (Fig. 1a).